Budesonide
Brand Names: Pulmicort Flexhaler, Tarpeyo, Pulmicort, Pulmicort Respules, Eohilia, Uceris
Methodology & AI Transparency ⓘ
Budesonide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Budesonide inhalation suspension is an inhaled corticosteroid indicated for: Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm ( 1 ) 1.1 Maintenance Treatment of Asthma Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.
- 2 Real-world patient consensus: Real-world cohort score of 88% across 21 de-identified Budesonide entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $25.06 wholesale mail-order against $61.40 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Budesonide: diarrhea (8.6%), abdominal discomfort (4.1%), vomiting (4.9%).
Ask our AI Specialists anything about Budesonide
Budesonide Mechanism, CYP450 Pathways & DailyMed Monograph
Budesonide inhalation suspension is an inhaled corticosteroid indicated for: Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm ( 1 ) 1.1 Maintenance Treatment of Asthma Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Limitations of Use: Budesonide inhalation suspension is NOT indicated for the relief of acute bronchospasm.
12.1 Mechanism of Action Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. In standard in vitro and animal models, budesonide has approximately a 200 fold higher affinity for the glucocorticoid receptor and a 1000 fold higher topical anti-inflammatory potency than cortisol (rat croton oil ear edema assay). As a measure of systemic activity, budesonide is 40 times more potent than cortisol when administered subcutaneously and 25 times more potent when administered orally in the rat thymus involution assay.
Clinical clearance of Budesonide (Corticosteroid) relies on cytochrome cyp3a4 biotransformation with dual hepatorenal elimination with a Elimination kinetics span 8 to 13 hours per Budesonide clinical pharmacology half-life; patients absorbing at Consistent 66%–78% gastrointestinal absorption profile for Budesonide bioavailability typically observe target onset around cmax attained 2–5 hours post-administration of budesonide.
FDA clinical labeling for Budesonide restricts administration in hypersensitivity to budesonide or any of the ingredients of budesonide inhalation suspension .; previous anaphylactoid or exfoliative reaction attributed to budesonide across 32 ug/1 Spray, Metered, 90 ug/1 Aerosol, Powder, .25 mg/2mL Suspension, 2 mg/1 Aerosol, Foam, 3 mg/1 Capsule, Delayed Release, with self-reported patient tracking dominated by diarrhea (8.6% of reports), nausea (7.6% of reports), headache (6.6% of reports).
Co-prescribing potent CYP3A4 inhibitors reduces metabolic elimination of Budesonide and prolongs half-life.
Systemic bioavailability and half-life of Budesonide respond to strong CYP3A4 enzymatic inhibition or induction.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Hypersensitivity to budesonide or any of the ingredients of budesonide inhalation suspension .
- Previous anaphylactoid or exfoliative reaction attributed to Budesonide
Logged Side-Effect Incidence (21 Reports)
Budesonide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Budesonide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and: What a 8,509-Participant Study Found BGF triple therapy improved symptoms and HRQoL vs dual therapies over 24 and 52 weeks in patients with moderate-to-very severe COPD. Respiratory medicine • 2021-01-15 • Phase III Randomized Trial | N = 8,509 | 96/100 | PMID 34171789 ↗ |
| Can This Approach Help? Inside the Latest Research on Budesonide as induction therapy for incomplete microscopic colitis: A randomised, Budesonide decreased the frequency of soft or watery stools and improved the patients' quality of life significantly in MCi, but the primary endpoint was not met due to the low sample size (type 2 error). United European gastroenterology journal • 2021-09-15 • Phase III Randomized Trial | N = 44 | 88/100 | PMID 34414678 ↗ |
| New Insights on Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic: What a 213-Participant Study Found In patients with EoE, BOS 2.0 mg twice daily was superior to placebo in improving histologic, symptomatic, and endoscopic outcomes over 12 weeks. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2022-03-15 • Phase III Randomized Trial | N = 213 | 88/100 | PMID 33887475 ↗ |
| Can This Approach Help? Inside the Latest Research on A Pilot compared against a dummy pill (placebo) Randomized Trial of Repeated High-dose magnesium appeared safe with only a modest possible benefit of medical readiness for discharge at 12 h. Journal of paediatrics and child health • 2026-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42605209 ↗ |
| Can This Approach Help? Inside the Latest Research on Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Both monocomponents contributed to albuterol-budesonide lung function efficacy. Chest • 2023-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37003355 ↗ |
Budesonide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.6631/unit (~$19.89/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $25.06 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $61.40 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $28.82 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
| Virtual Psychiatric Medication Management (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $39.00 consult | Program details |
Budesonide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Budesonide RxNorm Concept ID | 349094 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.6631 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $61.40 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $25.06 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 88.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Budesonide Patient Community, Cohort Filters & Dosage Logs
Cross-verified Budesonide (corticosteroid) monograph synthesizing RxNorm 349094, openFDA FAERS signals, and $25.06–$61.40 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Budesonide community threads and patient logs by age, biological sex, dosage, and treatment duration.